These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16750364)

  • 81. Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.
    Micheli F; Pasquarello A; Tedesco G; Hamprecht D; Bonanomi G; Checchia A; Jaxa-Chamiec A; Damiani F; Davalli S; Donati D; Gallotti C; Petrone M; Rinaldi M; Riley G; Terreni S; Wood M
    Bioorg Med Chem Lett; 2006 Aug; 16(15):3906-12. PubMed ID: 16730983
    [TBL] [Abstract][Full Text] [Related]  

  • 82. A Divergent SAR Study Allows Optimization of a Potent 5-HT2c Inhibitor to a Promising Antimalarial Scaffold.
    Calderón F; Vidal-Mas J; Burrows J; de la Rosa JC; Jiménez-Díaz MB; Mulet T; Prats S; Solana J; Witty M; Gamo FJ; Fernández E
    ACS Med Chem Lett; 2012 May; 3(5):373-7. PubMed ID: 24900481
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Identification of Spiro[chromene-2,4'-piperidine]s as Potent, Selective, and G
    Jiang G; Zhang B; Zhang X; Chen F; Qin W; Chen JL; Tian S; Shui W; Ye N
    ACS Med Chem Lett; 2024 Jan; 15(1):99-106. PubMed ID: 38229745
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Design, Synthesis, and Evaluation of Tetrasubstituted Pyridines as Potent 5-HT2C Receptor Agonists.
    Rouquet G; Moore DE; Spain M; Allwood DM; Battilocchio C; Blakemore DC; Fish PV; Jenkinson S; Jessiman AS; Ley SV; McMurray G; Storer RI
    ACS Med Chem Lett; 2015 Mar; 6(3):329-33. PubMed ID: 25815155
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Cascade bicyclizations of o-alkynyl aldehydes with thiazolium salts: a new access toward poly-functionalized indeno[2,1-b]pyrroles.
    Zhou P; Hao WJ; Zhang JP; Jiang B; Li G; Tu SJ
    Chem Commun (Camb); 2015 Aug; 51(65):13012-5. PubMed ID: 26178784
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity.
    Liu KK; Cornelius P; Patterson TA; Zeng Y; Santucci S; Tomlinson E; Gibbons C; Maurer TS; Marala R; Brown J; Kong JX; Lee E; Werner W; Wenzel Z; Vage C
    Bioorg Med Chem Lett; 2010 Jan; 20(1):266-71. PubMed ID: 19914063
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor.
    Sabb AL; Vogel RL; Welmaker GS; Sabalski JE; Coupet J; Dunlop J; Rosenzweig-Lipson S; Harrison B
    Bioorg Med Chem Lett; 2004 May; 14(10):2603-7. PubMed ID: 15109661
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Design and synthesis of pyridazinone-based 5-HT(2C) agonists.
    Allerton CM; Andrews MD; Blagg J; Ellis D; Evrard E; Green MP; Liu KK; McMurray G; Ralph M; Sanderson V; Ward R; Watson L
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5791-5. PubMed ID: 19716297
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists.
    Shimada I; Maeno K; Kazuta K; Kubota H; Kimizuka T; Kimura Y; Hatanaka K; Naitou Y; Wanibuchi F; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2008 Feb; 16(4):1966-82. PubMed ID: 18035544
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The design and synthesis of a tricyclic single-nitrogen scaffold that serves as a 5-HT2C receptor agonist.
    Huck BR; Llamas L; Robarge MJ; Dent TC; Song J; Hodnick WF; Crumrine C; Stricker-Krongrad A; Harrington J; Brunden KR; Bennani YL
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4130-4. PubMed ID: 16750364
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases.
    Wacker DA; Miller KJ
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):438-45. PubMed ID: 18600561
    [TBL] [Abstract][Full Text] [Related]  

  • 92. 5-HT2C receptor agonists as an innovative approach for psychiatric disorders.
    Rosenzweig-Lipson S; Dunlop J; Marquis KL
    Drug News Perspect; 2007 Nov; 20(9):565-71. PubMed ID: 18176661
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors.
    Aloyo VJ; Berg KA; Spampinato U; Clarke WP; Harvey JA
    Pharmacol Ther; 2009 Feb; 121(2):160-73. PubMed ID: 19109993
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors.
    Blaazer AR; Smid P; Kruse CG
    ChemMedChem; 2008 Sep; 3(9):1299-309. PubMed ID: 18666267
    [TBL] [Abstract][Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.